High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anti-C1q antibodies (anti-C1q) have been shown to correlate positively with systemic lupus erythematosus (SLE) nephritis. Several clinical studies indicated a high negative predictive value, suggesting that active lupus nephritis is rarely seen in patients with no anti-C1q. However, the true prevalence of anti-C1q at the time of active lupus nephritis has not been well established. The aim of this study was to determine prospectively the prevalence of anti-C1q in proven active lupus nephritis at the time of the renal biopsy. METHODS: In this prospective multi-centre study, we investigated adult SLE patients undergoing renal biopsy for suspected active lupus nephritis. Serum samples were taken at the time of the biopsy and analysed for the presence of anti-C1q in a standardized way. The activity of lupus nephritis was classified according to the renal histology. Biopsies were also analysed for the presence of glomerular IgG, C1q and C3 deposition. RESULTS: A total of 38 patients fulfilling at least 4/11 American College of Rheumatology (ACR) criteria for the diagnosis of SLE were included. Out of this, 36 patients had proliferative (class II, III or IV) and two had class V lupus nephritis. All but one patient with proliferative lupus nephritis were positive for anti-C1q (97.2%) compared with the 35% of control SLE patients with inactive lupus nephritis and 25% of SLE patients without lupus nephritis ever. All patients were positive for glomerular C1q (36/36) and 37/38 patients had glomerular IgG deposits. Anti-C1q strongly decreased during successful treatment. CONCLUSIONS: Anti-C1q have a very high prevalence in biopsy-proven active lupus nephritis, thus a negative test result almost excludes active nephritis. The data support the hypothesis of a pathogenic role of anti-C1q in lupus nephritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
The classification of glomerulonephritis in systemic lupus erythematosus revisited
Weening, J. J., ON Behalf of the International Society of Nephrology and Renal Pathology Society Working Group on the Classification Oflupus Nephritis, D'agati, V. D., Schwartz, M. M., Seshan, S. V., Alpers, C. E., Appel, G. B., Balow, J. E., Bruijn, J. A. N. A., Cook, T., et al. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00443.x · Cited by 1,652
Systemic Lupus Erythematosus, Complement Deficiency, and Apoptosis
Pickering, M. C., Botto, M., Taylor, P. R., Lachmann, P. J., & Walport, M. J. (2001) · Advances in Immunology · doi:10.1016/s0065-2776(01)76021-x · Cited by 544 · cited 1×
“C1q or C4, is strongly associated with the development of SLE [2].”
BackgroundC1q, Autoimmunity and Apoptosis
BOTTO, M. (2002) · Immunobiology · doi:10.1078/0171-2985-00141 · Cited by 289 · cited 1×
“An important hypothesis about the pathogenesis of systemic lupus erythematosus (SLE) assumes that the disease is driven by a defective clearance of dead and dying cells (apoptosis) [1].”
BackgroundTrouw, L. A., Groeneveld, T. W. L., Seelen, M. A., Duijs, J. M. G. J., Bajema, I. M., Prins, F. A., Kishore, U., Salant, D. J., Verbeek, J. S., Kooten, C. V., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421075 · Cited by 245
Marto, N., Bertolaccini, M. L., Calabuig, E., Hughes, G. R. V., & Khamashta, M. A. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.024943 · Cited by 201 · cited 2×
“Therefore, in order to determine the prevalence and negative predictive value of anti-C1q for the occurrence of proliferative lupus nephritis, we performed a prospective, multicentre study measuring anti-C1q in SLE patients undergoing renal biopsy for suspected active lupus nephritis and using a uniform test system [9…”
MethodAnti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis
Moroni, G., Trendelenburg, M., Del Papa, N., Quaglini, S., Raschi, E., Panzeri, P., Testoni, C., Tincani, A., Banfi, G., Balestrieri, G., et al. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80005-6 · Cited by 182
Self-citationChanges in antibodies to C1q predict renal relapses in systemic lupus erythematosus
Coremans, I. E. M., Spronk, P. E., Bootsma, H., Daha, M. R., van der Voort, E. A. M., Kater, L., Breedveld, F. C., & Kallenberg, C. G. M. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90595-2 · Cited by 176 · cited 1×
“Although many studies demonstrated a high prevalence of anti-C1q in active lupus nephritis, the data presented in other reports suggested lower negative predictive values for anti-C1q [8,13,22].”
ResultSiegert, C. E. H., Daha, M. R., Westedt, M. L., van der Voort, E., & Breedveld, F. C. (1991) · PubMed · Cited by 155
Cited by
Fanouriakis, A., Kostopoulou, M., Cheema, K., Anders, H.-J., Aringer, M., Bajema, I., Boletis, J., Frangou, E., Houssiau, F. A., Hollis, J., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-216924 · Cited by 825
Self-citationAutoantibodies in SLE: Specificities, Isotypes and Receptors
Dema, B., & Charles, N. (2016) · Antibodies · doi:10.3390/antib5010002 · Cited by 201
“Conversely, low levels of C1q are typically associated with disease flares and with the appearance of anti-C1q antibodies [80] which, in turn, are found in 20%–50% of SLE patients and in up to 100% of active proliferative LN patients [81].”
BackgroundRyan, B. J., Nissim, A., & Winyard, P. G. (2014) · Redox Biology · doi:10.1016/j.redox.2014.05.004 · Cited by 119
Autoantibodies against complement component C1q in systemic lupus erythematosus
Trendelenburg, M. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1279 · Cited by 48
“In particular, antiC1q levels and the percentage of SLE patients being positive for anti-C1q strongly dependent on the presence of active lupus nephritis at the time of sampling.(24,35) As a biomarker for the occurrence of proliferative lupus nephritis in patients with SLE, anti-C1q seem to be superior to determining…”
BackgroundSelf-citation
Metadata
- Authors
- Trendelenburg, M., Lopez-Trascasa, M., Potlukova, E., Moll, S., Regenass, S., Fremeaux-Bacchi, V., Martinez-Ara, J., Jancova, E., Picazo, M. L., Honsova, E., Tesar, V., Sadallah, S., & Schifferli, J.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-09-12
- Volume
- 21
- Issue
- 11
- Pages
- 3115-3121
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2116542983
- Cited by
- 180
- References
- 23
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. https://app.cochat.ai/papers/10.1093/ndt/gfl436
- The paper
- Trendelenburg, M., Lopez-Trascasa, M., Potlukova, E., Moll, S., Regenass, S., Fremeaux-Bacchi, V., Martinez-Ara, J., Jancova, E., Picazo, M. L., Honsova, E., Tesar, V., Sadallah, S., & Schifferli, J. (2006). High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfl436
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.